curasan AG

curasan AG: Worldwide distribution rights for Epi-Guide®

@@start.t1@@--------------------------------------------------------------------------------   ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for   the content of this announcement. --------------------------------------------------------------------------------@@end@@


Kleinostheim (euro adhoc) - curasan AG (WKN 549 453 8) has been granted worldwide distribution rights by Kensey Nash Corporation, USA, for Epi-Guide®, their bioresorbable membrane. This is an extension to a cooperation established in 2001 which has, so far, comprised sales in Germany, several other European countries and - since 2005 - the United States.

"International distribution rights open up additional revenue potential and create synergies in the expansion of marketing activities by way of supra-regional opinion leaders and by offering our distributors an even more balanced, and thus more attractive, product range", says Chairman Hans Dieter Roessler.

Epi-Guide® is a uniquely structured bioresorbable synthetic membrane with many applications within guided tissue regeneration (GTR) and guided bone regeneration (GBR). Suggestions for improvement, made to the manufacturer by curasan, significantly contributed to the development of a new generation of membranes which is now available as an optimized product.

About curasan AG: curasan AG (ISIN: DE 000 549 453 8), an exchange-listed company, is a leading innovator within the growth market of bone and tissue regeneration. The company has developed a comprehensive product range centred around its synthetic bone regeneration material Cerasorb®, for use in soft and hard tissue. With the REVOIS® implant system, the company's sales is focusing more prominently on the growth market of dental surgery/implantology. The majority of new products emerging from the substantial development pipeline are to be offered under licence within other medical fields. Please visit curasan's corporate website at

@@start.t2@@end of announcement                                                 euro adhoc 26.03.2007 11:03:00

ots Originaltext: curasan AG
Im Internet recherchierbar:

Further inquiry note:
Dr. Erwin Amashaufer, curasan AG, phone +49 6027 4686-465, email:
Andrea Weidner, curasan AG, phone +49 6027 4686-467, email:

Branche: Biotechnology
ISIN:      DE0005494538
WKN:        549453
Index:    CDAX, Classic All Share, Prime All Share
Börsen:  Frankfurter Wertpapierbörse / regulated dealing/prime
              Börse Berlin-Bremen / free trade
              Hamburger Wertpapierbörse / free trade
              Baden-Württembergische Wertpapierbörse / free trade
              Börse Düsseldorf / free trade
              Niedersächsische Börse zu Hannover / free trade
              Bayerische Börse / free trade

Weitere Meldungen: curasan AG

Das könnte Sie auch interessieren: